Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Company plans to appeal against CGST order related to alleged inadmissible input tax credit claims
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
Compared to a net loss of Rs 12 crore in FY25, the pharma major reported a consolidated turnaround in its financial performance
The company posted revenue of Rs. 703 crore in Q4 FY26
Pharma and biotech infrastructure firm targets 25–30% growth as Middle East and Africa emerge as key expansion markets
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
Analysts expect modest revenue growth but pressure on profitability in the March quarter
The collaboration combines Takara Bio’s large-scale testing technology with Resistomap’s data-driven AMR intelligence
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
Subscribe To Our Newsletter & Stay Updated
